Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lapatinib + docetaxel dose-escalation study in HER2-positive metastatic breast cancer
2007-007027-40Phase 2Active
- Sponsor
- Centre Georges-François Leclerc
- Start
- Jan 2008
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lapatinib and docetaxel in breast cancer, sponsored by Centre Georges-François Leclerc. Primary endpoint: Optimal tolerated regimen / recommended dose. Started Jan 2008; status: active.
02
Drugs
lapatinibdocetaxel
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2007-007027-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-007027-40.